Systematic review and metanalysis establish dermatologic adverse events as a positive predictor of survival in hepatocellular carcinoma patients treated with sorafenib

2018 ◽  
Vol 68 ◽  
pp. S195
Author(s):  
A. Diaz-Gonzalez ◽  
M. Sanduzzi-Zamparelli ◽  
V. Sapena ◽  
F. Torres ◽  
N. Llarch ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Adverse Events ◽  
Dermatologic Adverse Events

scholarly journals Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events

Hepatology ◽  
2018 ◽  
Vol 67 (2) ◽  
pp. 612-622 ◽  
Author(s):  
Jordi Rimola ◽  
Álvaro Díaz‐González ◽  
Anna Darnell ◽  
María Varela ◽  
Fernando Pons ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Adverse Events ◽  
Complete Response ◽  
Dermatologic Adverse Events

scholarly journals Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis

2013 ◽  
Vol 2 (6) ◽  
pp. 862-871 ◽  
Author(s):  
Kenya Yamanaka ◽  
Marius Petrulionis ◽  
Shibo Lin ◽  
Chao Gao ◽  
Uwe Galli ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Adverse Events ◽  
Therapeutic Potential ◽  
Meta Analysis

scholarly journals First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

2021 ◽  
Vol 11 ◽  
Author(s):  
Wenfeng Liu ◽  
Bing Quan ◽  
Shenxin Lu ◽  
Bei Tang ◽  
Miao Li ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Clinical Trials ◽  
Adverse Events ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Cochrane Central Register ◽  
First Line ◽  
Unresectable Hepatocellular Carcinoma

ObjectiveSeveral new first-line treatments were recently approved for unresectable hepatocellular carcinoma (HCC). In this meta-analysis, we compare the efficacy and safety of first-line systemic treatments to provide information for clinical decision making in unresectable HCC.MethodsPubmed, Science Direct, Web of Science, Scopus, Ovid MEDLINE, Embase, Google Scholar, the Cochrane Library, EMbase, CNKI, CBM, VIP, and the Wanfang databases, as well as the Cochrane Central Register of Controlled Trails were searched for randomized clinical trials evaluating the efficacy of first-line chemotherapy, molecular targeted therapy, or immunotherapy for unresectable HCC. Hazard ratios with 95% confidence intervals (CIs) were calculated to explore the effects of various treatment options on overall survival (OS) and progression-free survival (PFS), whereas odd ratios with 95% CIs were used for adverse events (AEs) and serious adverse events (SAEs). A network meta-analysis was performed to synthesize data and for direct and indirect comparisons between treatments. The cumulative ranking curve (SUCRA) and P score were used to rank treatments. The risk of bias across studies was assessed graphically and numerically using the funnel plot and Egger’s regression test.ResultsFifteen studies including 9005 patients were analyzed. Sintilimab plus bevacizumab, atezolizumab plus bevacizumab, and donafenib had better OS outcomes than sorafenib. Sintilimab plus bevacizumab, atezolizumab plus bevacizumab, lenvatinib, and linifanib had better PFS outcomes than sorafenib. The results of network meta-analysis showed that sintilimab plus bevacizumab was associated with the best OS and PFS. Egger’s tests indicated that none of the included studies had obvious publication deviation.ConclusionSintilimab plus bevacizumab showed the best OS and PFS outcomes with no additional AEs or SAEs. Thus, sintilimab plus bevacizumab may be a better first line choice for the treatment of patients with unresectable HCC.Systematic Review RegistrationPROSPEROI [https://www.crd.york.ac.uk/PROSPERO/index.php], identifier CRD42021269734.

scholarly journals A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies

2015 ◽  
Vol 23 (8) ◽  
pp. 2231-2244 ◽  
Author(s):  
Alexandre Chan ◽  
Michael C. Cameron ◽  
Benjamin Garden ◽  
Christine B. Boers-Doets ◽  
Katja Schindler ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adverse Events ◽  
Patient Reported Outcome ◽  
Cancer Therapies ◽  
Patient Reported ◽  
Targeted Cancer Therapies ◽  
Dermatologic Adverse Events

scholarly journals Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 426
Author(s):  
Josep Corominas ◽  
Victor Sapena ◽  
Marco Sanduzzi-Zamparelli ◽  
Cristina Millán ◽  
Esther Samper ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
T Cells ◽  
Adverse Events ◽  
Immune Suppression ◽  
Immune Checkpoints ◽  
Advanced Hepatocellular Carcinoma ◽  
Activation Markers ◽  
Immune Exhaustion ◽  
Increased Risk ◽  
Dermatologic Adverse Events

Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1+ cells express activation markers, T DNAM-1+ cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.

A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors

2018 ◽  
Author(s):  
Filette Jeroen de ◽  
Corina Andreescu ◽  
Filip Cools ◽  
Bert Bravenboer ◽  
Brigitte Velkeniers
Keyword(s):  
Systematic Review ◽  
Adverse Events ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document